Rigel Pharmaceuticals Q3 revenue slightly beats estimates
RIGL•Rigel Pharmaceuticals reported Q3 revenue of $80.9 million, slightly above the $80.1 million consensus estimate. Net product sales rose 13% year over year, and the company forecast 2026 total revenue of $290 million to $295 million.
1. Quarterly results
Rigel Pharmaceuticals’ Q3 revenue was $80.9 million, slightly above the $80.1 million consensus estimate. Net product sales increased 13% year over year, while net income declined as research and development and commercial launch expenses rose.
2. Products and outlook
Initial sales of VEPPANU contributed $6.6 million in Q3 net product sales. Modest growth in TAVALISSE and strong growth in REZLIDHIA offset lower GAVRETO sales. Rigel expects 2026 total revenue of $290 million to $295 million, including net product sales of $255 million to $260 million and contract revenue of about $35 million.
